Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 marketed · 17 in Phase 3

Quick facts

Marketed products

Fluorouracil Injection · Oncology
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.

Phase 3 pipeline

BCG for Injection · Oncology
BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and attack cancer cells, particularly in the bladder.
Calcium Folinate Injection · Oncology
Calcium folinate is a reduced form of folic acid that acts as a cofactor in one-carbon transfer reactions, supporting DNA synthesis and cell division.
Epirubicin Hydrochloride for Injection · Oncology
Epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells.
Gemcitabine and cisplatin / carboplatin · Oncology
Gemcitabine and cisplatin/carboplatin is a chemotherapy combination that damages cancer cell DNA through complementary mechanisms to inhibit tumor growth.
Hydroxycamptothecin for Injection · Oncology
Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells.
Mitomycin for Injection · Oncology
Mitomycin is an antibiotic that alkylates DNA, creating cross-links that prevent DNA replication and transcription, leading to cell death.
Pirarubicin Hydrochloride for Injection · Oncology
Pirarubicin Hydrochloride for Injection is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in cancer cells.
Placebo、CAPOX · Oncology
CAPOX is a chemotherapy regimen that combines capecitabine and oxaliplatin to treat cancer.
platinum-based dual-agent chemotherapy · Oncology
Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells.
SHR-1501 for Injection · Oncology
SHR-1501 is a recombinant human anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and PD-1/B7-1, thereby releasing immune checkpoint inhibition and enhancing anti-tumor T-cell responses.
SHR-1701、CAPOX · Oncology
SHR-1701 is a PD-L1 inhibitor combined with CAPOX chemotherapy (capecitabine and oxaliplatin) to enhance anti-tumor immunity while delivering cytotoxic chemotherapy.
SHR-A1811 for Injection · Oncology
SHR-A1811 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
SHR-A2009 ; Aumolertinib · Oncology
Aumolertinib is a third-generation EGFR tyrosine kinase inhibitor that selectively targets EGFR mutations, including T790M resistance mutations, to inhibit tumor cell proliferation.
SHR-A2009 monotherapy · Oncology
SHR-A2009 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
SHR-A2102 and Adebrelimab · Oncology
SHR-A2102 and Adebrelimab are anti-PD-1 monoclonal antibodies that inhibit the PD-1/PD-L1 interaction.
TAS-102, Regorafenib , Fruquintinib · Oncology
TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2).
tislelizumab, and platinum-based chemotherapy
Tislelizumab is a monoclonal antibody that targets and binds to PD-1, blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune response against cancer cells.

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Suzhou Suncadia Biopharmaceuticals Co., Ltd.

What are Suzhou Suncadia Biopharmaceuticals Co., Ltd.'s marketed drugs?

Top marketed products include Fluorouracil Injection.

What is Suzhou Suncadia Biopharmaceuticals Co., Ltd.'s pipeline?

Suzhou Suncadia Biopharmaceuticals Co., Ltd. has 17 drugs in Phase 3, 12 in Phase 2, 15 in Phase 1. Late-stage candidates include BCG for Injection, Calcium Folinate Injection, Epirubicin Hydrochloride for Injection, Gemcitabine and cisplatin / carboplatin.

Fluorouracil Injection · Oncology
Sector hub: All tracked pharma companies